Interleukin 4 Is Localized to and Released by Human Mast Cells

By P. Bradding, I. H. Feather, P. H. Howarth, R. Mueller,* J. A. Roberts, K. Britten, J. P. A. Bews,* T. C. Hunt, Y. Okayama, C. H. Heusser,* G. R. Bullock,* M. K. Church, and S. T. Holgate

Summary

Recent attention has focused on the T helper type 2 (Th2) lymphocyte as a source of interleukin 4 (IL-4) in allergic disease. However, Th2 cells themselves require a pulse of IL-4 to initiate this synthesis. Here we provide immunohistochemical evidence of IL-4 localization to human mast cells of the skin and respiratory tract, and demonstrate that immunoglobulin E–dependent stimulation of purified human lung mast cells leads to the rapid release of IL-4 into the extracellular environment. We propose that mast cell activation in an allergic response provides a rapid and local pulse of IL-4 into the local environment essential for the triggering of T lymphocytes into sustained IL-4 production and to initiate inflammatory cell accumulation and activation.

Materials and Methods

Human Subjects and Biopsy Specimens. Nasal biopsies were taken from the inferior or inferomedial edge of the inferior turbinate of four patients with allergic perennial rhinitis using 2-mm cupped Hartman's forceps (Medicom, Tuttlingen, Germany) under tetracaine local anesthesia. Bronchial biopsies were taken from the right middle lobe carina in four perennial allergic asthmatic patients via a fiber-optic bronchoscope (BFIT20; Olympus Company, Tokyo, Japan) using alligator forceps (Olympus FB15E) (11). All patients gave written informed consent and the biopsy procedures were approved by the Southampton University and Hospitals Ethical Committee. In each instance the biopsy specimens were fixed in ice-cooled acetone containing the protease inhibitors iodoacetamide and PMSF, then stored for 24 h at −20 °C before processing into glycol methacrylate (GMA). Biopsies were placed in acetone, then methylbenzoate for 15 min each at room temperature, transferred to GMA JB4 solution (Polysciences, Northampton, UK) at 4°C, followed by embedding in GMA resin.

Immunohistochemistry of Biopsy Specimens. For immunohistochemistry, 2-μm sections were cut by ultramicrotomy, floated on 0.2% ammonia solution in water for 1 min, and dried at room temperature for 1–4 h. Sections were pretreated with 10 ml 0.1% sodium azide solution containing 100 μl 30% hydrogen peroxide for 30 min to inhibit endogenous peroxidase. Mouse IgG1 mAbs 3H4 and 4D9 to human IL-4 (12), AA1 to mast cell tryptase, anti-CD3, and anti-CD4 were applied to sequential sections. A biotinylated rabbit anti-mouse (Dako Ltd., High Wycombe, UK) second stage was applied and subsequently demonstrated using the streptavidin–biotin peroxidase complex detection system. Aminothiethylcarbazole (AEC) was used as chromogen giving a red reaction product, and sections were counterstained in Mayers hematoxylin. Control slides were similarly treated, either with the primary antibody omitted, or in the presence of an unrelated mouse IgG1 mAb at the same concentration as the anti-IL-4 antibodies.
Four double immunostaining sections were initially treated with the first antibody as described using the streptavidin-biotin peroxidase detection system. This process was then repeated for the second antibody but by utilizing the streptavidin-biotin alkaline phosphatase detection system (Dako Ltd.) using fast blue B.B as the chromogen. No counterstain was applied. Controls were performed with no antibody, either the anti-tryptase, anti-CD3, or anti-IL-4 antibody absent, and with each antibody applied first, to show that the detection system for the second antibody did not crossreact with the first antibody.

**Mast Cell Purification.** Foreskin mast cells were dispersed from circumcision specimens using collagenase (1.5 mg/ml) and hyaluronidase (0.75 mg/ml) as previously described (13). The isolated cells were layered onto a discontinuous gradient of 60-80% Percoll (density, 1.076-1.1 g/ml) and centrifuged at 500 g for 20 min at 4°C. Mast cells at the bottom of the gradient and between the 70/80% interface were 90% pure. T lymphocytes were removed by incubation of resuspended cells for 30 min at 4°C with magnetic beads coated with a mAb specific for the CD2 T cell antigen (Dynal, Oslo, Norway). Two 15-min exposures to a magnet removed 99% of CD2-positive T cells. Lung mast cells were dispersed from macroscopically normal human lung, obtained within 1 h of resection (Leica UK Limited, Milton Keynes, UK) has shown that the percentage of IL-4-containing cells that were also tryptase positive ranged from 78 to 100%, while the number of tryptase-positive cells that were also IL-4 positive ranged from 68 to 85%. No IL-4 immunoreactivity was localized to either CD3- or CD4-positive T cells with either double staining or comparison of sequential sections. No crossreaction was observed in the double-stained controls.

**Immunohistochemistry of Purified Mast Cells.** For immunocytochemical staining, purified mast cells were fixed in buffered 4% paraformaldehyde (20 min), and cytospin preparations were made. The mast cells were then stained for IL-4 with three mAbs, 3H4, 4D9, and 8F12 (12), using the alkaline phosphatase anti-alkaline phosphatase (APAAP) detection system with fastred as the chromogen for skin cells and fast blue as the chromogen for the lung cells to help distinguish cells from dynabeads. Negative controls were performed with primary antibody absent and an unrelated mouse IgG1 mAb. Specificity of immunostaining was demonstrated in Chinese hamster ovary (CHO) cells transfected with cDNA for human IL-4. IL-4 immunoreactivity was shown with the mAb 3H4, which could be effectively inhibited when the 3H4 mAb was preincubated with rhIL-4 (Fig. 1). Positive immunostaining of IL-4-transfected CHO cells was also observed with the anti-IL-4 mAbs 4D9 and 8F12.

**IL-4 Release by Purified Mast Cells.** After purification mast cells were resuspended in cold HBSS* and allowed to warm slowly to room temperature. Aliquots of the cell suspension were made (225 μl containing ~5-10 x 10⁴ mast cells/tube) and preincubated for 15 min before addition of 25 μl of 10-10° concentrated anti-IgE or HBSS* (control). Cells were then incubated for 1, 2, 4, or 6 h, and the release reaction was stopped by centrifugation (5 min, 500 g, 4°C). Supernatants were decanted and frozen at −80°C. For histamine analysis, TCA was added to a final concentration of 5% before freezing. Histamine was measured spectrophotofluorimetrically and IL-4 assayed by ELISA, which has a lower detection limit of 40 pg/ml of IL-4 and a coefficient of variation of 4% in the range of 60-2,000 pg/ml.

**Results and Discussion.** In all the biopsies from both the rhinitic and asthmatic subjects, cells staining positively for IL-4 were present (Fig. 2). No significant immunostaining was identified in either the absence of antibody or in the presence of an unrelated antibody control. On identifying the same nucleated, IL-4-immunoreactive cell in adjacent 2-μm sections, positive staining was seen with both the 3H4 and 4D9 mAbs, which recognize different epitopes on human IL-4, thereby confirming the identity of immunoreactivity as IL-4. When immunostaining with AA1, an antibody against mast cell tryptase, was also performed in adjacent sections (Fig. 2), or in the same section (Fig. 3), IL-4 immunoreactivity was found to be localized to mast cells. Comparison of sequential sections stained in the eight biopsies using the camera-lucida system (Leica UK Limited, Milton Keynes, UK) has shown that the percentage of IL-4-containing cells that were also tryptase positive ranged from 78 to 100%, while the number of tryptase-positive cells that were also IL-4 positive ranged from 68 to 85%. No IL-4 immunoreactivity was localized to either CD3- or CD4-positive T cells with either double staining or comparison of sequential sections. No crossreaction was observed in the double-stained controls.

Investigation of IL-4 immunoreactivity using the anti-human IL-4 antibodies 3H4, 4D9, and 8F12 in mast cells, dispersed from both human lung and skin purified to >95%, confirmed the intracellular localization of IL-4 (Fig. 4). Anti-IgE challenge resulted in specific release of IL-4 from purified human lung mast cells (n = 3), with mean levels in cells challenged with anti-IgE and unchallenged controls of 13.2 ng/10⁶ cells and <0.5 ng/10⁶ cells, respectively (Fig. 5).

The immunocytochemical and ELISA techniques we have used, chosen in preference to estimation of mRNAs by in situ hybridization, which does not always reflect protein synthesis and cannot detect storage, have clearly demonstrated that human mast cells contain and release IL-4. The studies with biopsies and isolated cells have allowed us to examine mast cells from several tissue sites, all of which show IL-4 immunoreactivity with three different mAbs. This observation strongly suggests that the presence of IL-4 is not restricted to one mast cell subset, the mast cells of the skin and lung being phenotypically distinct (14). Thus, mast cells at both connective tissue and mucosal sites may participate in allergic inflammation through IL-4 release. In experiments to assess IL-4 release from lung mast cells, we have used an ELISA to quantitate IL-4 after anti-IgE challenge. The observation that anti-IgE released similar amounts of IL-4 at 1, 2, 4, and 6 h suggests that this cytokine seems to be present within the cells in a preformed state similar to that reported for TNF-α (15).

The specificity of our immunostaining for IL-4 is suggested by several factors. First, in the tissue section, the two specific IL-4 antibodies used, 3H4 and 4D9, stain the same cells in spite of reacting with different epitopes on human IL-4, while an isotype control antibody at the same Ig concentration was negative. Second, with the purified cells, the three antibodies used, 3H4, 4D9, and 8F12, all give positive staining, whereas
Cytocentrifuged IL-4-transfected (CHO) cells (top) and non-transfected CHO cells (middle) showing positive and negative staining, respectively, with mAb 3H4. Incubation of mAb 3H4 with an excess of IL-4 before staining of transfected cells greatly reduced IL-4 immunostaining (bottom).

An isotype control was again negative. Third, CHO cells transfected with the human IL-4 gene and known to secrete large quantities of IL-4 stained positively with the IL-4 antibodies, whereas CHO cells without gene transfection were negative. Incubation of antibodies with IL-4 before staining greatly reduced staining of IL-4-positive CHO cells but was unhelpful in tissue sections due to marked subsequent background staining, probably due to nonspecific binding of immune complexes to resin sections, or binding of immune complexes via the IL-4 receptor, as neither antibodies employed in the tissue sections were neutralizing.

These findings have considerable relevance to the pathogenesis of chronic allergic inflammation and in particular for the role of the tissue mast cell in its initiation. IL-4 has many effects that promote allergic inflammation. These include:

Figure 1. Cytocentrifuged IL-4-transfected (CHO) cells (top) and non-transfected CHO cells (middle) showing positive and negative staining, respectively, with mAb 3H4. Incubation of mAb 3H4 with an excess of IL-4 before staining of transfected cells greatly reduced IL-4 immunostaining (bottom).

Figure 2. Immunohistological staining with antibodies 3H4 against human IL-4 (top), AA1 against mast cell tryptase (middle), and 4D9 also against human IL-4 (bottom) in sequential 2-μm sections of a mucosal biopsy from a patient with atopic asthma showing cellular staining with both anti-IL-4 antibodies and the anti-mast cell tryptase antibody.
upregulation of IgE synthesis (1); stimulation of T cell proliferation and Th2 cell development (6, 7, 16); induction of MHC class II molecules on B cells and monocytes (17, 18); induction of FcER\(_{\alpha}\) (CD23) on B cells and macrophages (17, 19); induction of LFA-1 and LFA-3 on B cells (20); activation of macrophages (21); proliferation of fibroblasts (22); induction of VCAM-1 on endothelial cells (23); increased mast cell basal and stimulated histamine release (24); the promotion of eosinophil and mast cell accumulation at the site of allergic reactions (25, 26); and mast cell growth and maturation (27).

The source of IL-4 necessary to maintain these responses is considered to be the T lymphocyte, particularly its Th2 subset (28). However the Th2 lymphocyte itself requires IL-4 to initiate and support its development and cytokine synthesis (6, 7). It is our hypothesis that the release of IL-4 from the mast cell after IgE-dependent activation provides a localized initiating stimulus for the activation of Th2 cells. Furthermore, we suggest that mast cell cytokine release within minutes of allergen provocation plays a major role in the early accumulation of inflammatory cells observed. Thus, in addition to being the source of histamine and eicosanoids, which are responsible for most of the symptoms of the early phase of an allergic response, mast cells may play an obligatory role in the initiation, and possibly the maintenance, of allergic inflammation through the production and release of IL-4, TNF-\(\alpha\), and possibly other cytokines.
We thank Mrs. C. Martin for typing the manuscript.

This work was supported by a programme grant from the Medical Research Council.

Address correspondence to P. Bradding, Immunopharmacology Group, Faculty of Medicine, University of Southampton, Level D, Centre Block, Southampton General Hospital, Tremona Road, Southampton SO9 4XY, UK.

Received for publication 28 January 1992 and in revised form 20 July 1992.

References

1. Coffman, R.L., J. Ohara, M.W. Bond, J. Carty, E. Zlotnik, and W.E. Paul. 1986. B-cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B-cells. J. Immunol. 136:4538.

2. Finkelman, F.D., I.M. Katona, J.F. Urban, C.M. Snapper, J. Ohara, and W.E. Paul. 1986. Suppression of in vivo polyclonal IgE responses by monoclonal antibody to the lymphokine BSF-1. Proc. Natl. Acad. Sci. USA. 83:9675.

3. Kuhn, R., K. Rajewsky, and W. Muller. 1991. Generation and analysis of interleukin-4 deficient mice. Science (Wash. DC). 254:707.

4. Tepper, R.I., D.A. Levinson, B.Z. Stranger, J. Campos-Torres, A.K. Abbas, and P. Leder. 1990. IL-4 induces allergic-like inflammatory disease and alters T-cell development in transgenic mice. Cell. 62:457.

5. Kay, A.B., Sun Ying, V. Varney, M. Gaga, S.R. Durham, R. Moqbel, A.J. Wardlaw, and Q. Hamid. 1991. Messenger RNA expression of the cytokine gene cluster, interleukin 3 (IL-3), IL-5, IL-6, and granulocyte/macrophage colony-stimulating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects. J. Exp. Med. 173:775.

6. Le Gros, G., S.Z. Ben-Sasson, R. Seder, F.D. Finkelman, and W.E. Paul. 1990. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. J. Exp. Med. 172:921.

7. Swain, S.L., A.D. Weinberg, M. English, and G. Huston. 1990. IL-4 directs the development of TH2-like helper effectors. J. Immunol. 145:3796.

8. Plaut, M., J.H. Pierie, C.J. Watson, J. Hanley-Hyde, R.P. Nordan, and W.E. Paul. 1989. Mast cell lines produce lymphokines in response to cross-linkage of FcRI or to calcium ionophores. Nature (Lond.). 339:64.

9. Ben-Sasson, S.Z., G. Le Gros, D.H. Conrad, F.D. Finkelman, and W.E. Paul. 1990. Cross-linking Fc receptors stimulates splenic non-B, non-T cells to secrete interleukin 4 and other lymphokines. Proc. Natl. Acad. Sci. USA. 87:1421.

10. Piccini, M.P., D. Macchia, P. Parronchi, M.G. Giudizi, D. Bani, R. Alerini, A. Grossi, M. Ricci, E. Maggi, and S. Romagnani. 1991. Human bone-marrow non B, non-T-cells produce interleukin 4 in response to cross-linkage of Fc, and Fcy receptors. Proc. Natl. Acad. Sci. USA. 88:8656.

11. Djukanović, R., J.W. Wilson, C.K.W. Lai, S.T. Holgate, and P.H. Howarth. 1991. The safety aspects of fibrinopeptide bronchoscopy, bronchoalveolar lavage, and endobronchial biopsy in asthma. Am. Rev. Respir. Dis. 143:772.

12. Andersson, U., J. Andersson, A. Lindfors, K. Wagner, G. Muller, and C.H. Heussser. 1990. Simultaneous production of interleukin-2, interleukin-4 and interferon-γ by activated human blood monocytes. Eur. J. Immunol. 20:1591.

13. Lowman, M.A., P.H. Rees, R.C. Benyon, and M.K. Church. 1988. Human mast cell heterogeneity. Histamine release from mast cells dispersed from skin, lung, adenoids, tonsils and colon in response to IgE-dependent and non-immunological stimuli. J. Allergy Clin. Immunol. 81:590.

14. Irani, A.A., N.M. Schelter, S.S. Craig, G. Deblois, and L.B. Schwartz. 1986. Two types of mast cells that have distinct neutral protease compositions. Proc. Natl. Acad. Sci. USA. 83:4464.

15. Gordon, J.R., and S.J. Galli. 1991. Release of both preformed and newly synthesized tumour necrosis factor α(TNF-α)/cachectin by mouse mast cells stimulated via the Fc(RI). A mechanism for the sustained action of mast cell-derived TNF-α during IgE-dependent biological responses. J. Exp Med. 174:103.

16. Spits, H., H. Ysel, Y. Takebe, N. Araì, T. Yokota, F. Cee, K.I. Araì, J. Banchereau, and J.E. de Vries. 1987. Recombinant interleukin-4 promotes the growth of human T-cells. J. Immunol. 139:842.

17. Rousset, F., R. De Waal Malefijt, B. Sliërendregt, J.P. Aubry, J.Y. Bonnefoy, T. Defrance, J. Banchereau, and J.E. de Vries. 1988. Regulation of Fc receptor for IgE (CD23) and class II MHC antigen expression on Burkitts lymphoma cell lines by human IL-4 and IFN-gamma. J. Immunol. 140:2625.

18. Te Velde, A.A., J.P.G. Klopmp, B.A. Yard, J.E. de Vries, and C.G. Figdor. 1988. Modulation of phenotypic and functional properties of human blood monocytes by IL-4. J. Immunol. 140:1548.

19. Vercelli, D., H.H. Jabara, B.W. Lee, N. Woodland, R.S. Geha, and D.Y. Leung. 1988. Human recombinant interleukin 4 induces FeR/CD23 on normal human monocytes. J. Exp Med. 167:1406.

20. Rousset, F., M. Billaud, D. Blanchard, C. Agdor, G.M. Lenoir, H. Spits, and J.E. de Vries. 1989. IL-4 induces LFA-1 and LFA-3 and Burkitts lymphoma cell lines. J. Immunol. 143:1490.

21. Crawford, R.M., D.S. Finbloom, J. Ohara, W.E. Paul, and M.S. Melzter. 1987. B cell stimulation factor-1 (interleukin 4) activates macrophages for increased tumouricidal activity and expression of la antigens. J. Immunol. 139:135.

22. Monroe, J.G., S. Haldar, M.A. Lowman, M.A., P.H. Rees, R.C. Benyon, and M.K. Church. 1988. Lymphokine regulation of inflammatory processes: interleukin 4 promotes the growth of human T-cells. J. Immunol. 139:842.

23. Masinovsky, B., D. Urdal, and W.M. Gallatin. 1990. IL-4 acts synergistically with IL-1 and promote lymphocyte adhesion to microvascular endothelium by induction of vascular cell adhesion molecule-1. J. Immunol. 145:2886.

24. Levi-Schaffer, F., V. Segal, and M. Shalit. 1991. Effects of in-
terleukins on connective tissue type mast cells cultured with fibroblasts. *Immunology.* 72:174.

25. Tepper, R.I., P.K. Pattengale, and P. Leder. 1989. Murine interleukin-4 displays potent anti-tumour activity in vivo. *Cell.* 57:503.

26. Madden, K.B., J.F. Urban, H.J. Ziltener, J.W. Schrader, F.D. Finkleman, and M. Katona. 1991. Antibodies to IL-3 and IL-4 suppress helminth-induced intestinal mastocytosis. *J. Immunol.* 147:1387.

27. Tsuji, K., T. Nakahata, M. Takagi, T. Kobayashi, A. Ishiguro, T. Kikuchi, K. Maganuma, K. Koike, A. Miyajima, K. Arai, and T. Akabane. 1990. Effects of interleukin-3 and interleukin-4 on the development of “connective tissue-type” mast cells in interleukin-3 supports their survival and interleukin-4 triggers and supports their proliferation synergistically with interleukin-3. *Blood.* 75:421.

28. Mosmann, T.R., H. Cherwinski, M.W. Bond, M.A. Giedlin, and R.L. Coffman. 1986. Two types of murine helper T-cell clone. Definition according to profiles of lymphokine activities and secreted proteins. *J. Immunol.* 136:2348.